Advanced Genetic Study and Pilot Newborn Screening for Disorders of Pyruvate Metabolism
Advanced Genetic Study and Pilot Newborn Screening for Disorders of Pyruvate Metabolism
批准号:
10472600
负责人:
Jirair K Bedoyan
金额:
$16.1万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-30 至 2024-08-31
关键词:
AffectAgeAge of OnsetAmericanAreaAtaxiaBiological MarkersBrainCarbohydratesCessation of lifeChildhoodClinicalClinical TreatmentClinical Trials DesignCognitiveCollaborationsDataDatabasesDefectDiagnosisDiseaseEarly DiagnosisEarly InterventionEligibility DeterminationEnzymesEpilepsyFrequenciesFunctional disorderFutureGenesGenetic Predisposition to DiseaseGenetic studyGoalsHealthHigh-Throughput Nucleotide SequencingHospitalizationImpairmentIncidenceInstitutionInternationalIntervention TrialLactic AcidosisLanguage DevelopmentLinkMeasurableMedical centerMitochondriaMitochondrial DiseasesMolecularMutationNatural HistoryNeonatalNeonatal ScreeningNeurologicNeuropathyNewborn InfantOhioOutcomeParticipantPatientsPrevalencePrincipal InvestigatorProductionProtocols documentationPyruvate Dehydrogenase Complex Deficiency DiseasePyruvate Metabolism PathwayRare DiseasesRegistriesReportingResearch Project GrantsSiteSleep disturbancesSocial FunctioningSpeechSubgroupTechnologyTestingTherapeutic InterventionTimeWorkbiobankbrain malformationcognitive disabilitycognitive functiondisease classificationeffective therapyexome sequencinggenetic analysisgenomic datahealth care deliveryimprovedinfancyketogenic dietnext generation sequencingnovelnovel therapeuticsoxidationpatient registryprogramsrecruitscreening panelscreening programsurvival prediction
中文摘要
丙酮酸脱氢酶复合物缺陷(PDCD)是线粒体损伤的主要类型。
疾病,限制碳水化合物的氧化以产生能量,这是特别重要的
在大脑里。PDCD是NAMDC登记系统中第二个最常见的条目,
参与者有多种线粒体酶缺陷。生存率的最佳预测指标,
PDCD患者的认知结果似乎与发病年龄有关,新生儿
通常与早逝相关的表现,以及与
更好的生存率和正常或轻度至重度认知障碍。平均年龄和中位年龄
诊断为PDCD的时间分别为31和12个月。我们有次级PDC
缺陷受试者分为三个不同的组,具有重要的临床后果。使用
生酮饮食目前是PDCD特定亚类的主要治疗干预,但
在其他亚类的受试者中可能无效和/或致命。建议的“先进
PDC缺乏症的遗传研究和新生儿筛查试点”是
我们在以前的“PDC的自然历史和高级遗传研究”中完成的工作
缺陷”,其中我们a)鉴定了与丙酮酸相关的新的和已知的基因,
代谢,B)已将自然史和分子数据与NAMDC登记处相结合,
其他数据库,c)将PDCD受试者细分为三组-主要特异性-
原发性全身性和继发性PDCD,和d)注意到患者诊断为原发性特异性
PDCD将是从生酮饮食开始获益最多的人。我们的目标#1
继续使用已建立的先进遗传学方法鉴定PDCD的新遗传病因,
分析技术,并在需要时进行功能确认,
使我们能够更好地了解这种疾病的病理生理学,以便将来控制临床
治疗干预试验。我们的目标#2是首次试点新生儿筛查(NBS)
使用生物标志物和特定分子测试的协议,目的是诊断新生儿
初级特异性PDCD,用于生酮饮食的早期干预,以改善长期健康,
认知结果。这个试点NBS PDC协议是俄亥俄州范围内的奋进,包括两个
其他NAMDC站点,它们总共占所有线粒体
NAMDC登记处的疾病。
英文摘要
Pyruvate dehydrogenase complex deficiencies (PDCD) are a major class of mitochondrial
diseases, limiting oxidation of carbohydrate for energy production, which is especially important
in the brain. PDCD is the second most common entry within the NAMDC Registry among registry
participants with multiple mitochondrial enzyme defects. The best predictor of survival and
cognitive outcome in those affected with PDCD appears to be the age of onset, with neonatal
presentations typically associated with early death, and childhood onset cases associated with
better survival and with normal or mild to severe cognitive disability. The mean and median ages
of diagnosis of PDCD are about 31 and 12 months, respectively. We have sub-classified PDC
deficient subjects into three different groups with important clinical consequences. Use of
ketogenic diets is currently the main therapeutic intervention in a specific subclass of PDCD, but
can be ineffective and/or lethal in subjects from the other subclasses. The proposed "Advanced
Genetic Study and Pilot Newborn Screening for PDC deficiency" is in part a continuation of the
work we have accomplished in our previous "Natural History and Advanced Genetic Study of PDC
deficiencies", where we have a) identified novel and known genes associated with pyruvate
metabolism, b) have integrated natural history and molecular data with the NAMDC Registry and
other databases, c) have sub-classified PDCD subjects into three groups - primary specific-
primary generalized- and secondary-PDCD, and d) noted that patients diagnosed primary-specific
PDCD would be the ones who would benefit most from initiation of a ketogenic diet. Our Aim #1
is to continue identifying novel genetic etiologies for PDCD using established advanced genetic
analysis technologies in conjunction with functional confirmation when needed, which would
enable better understanding of the pathophysiology of this disorder for future controlled clinical
therapeutic intervention trials. Our Aim #2 is to pilot for the first time a newborn screening (NBS)
protocol using biomarkers and specific molecular tests with the goal of diagnosing newborns with
primary-specific PDCD for early intervention with ketogenic diet for better long-term health and
cognitive outcomes. This pilot NBS PDC protocol is an Ohio-wide endeavor that includes two
other NAMDC sites, which together constitute about 20% of all recruits with mitochondrial
disorders in the NAMDC Registry.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advanced Genetic Study and Pilot Newborn Screening for Disorders of Pyruvate Metabolism
-
批准号:10023969
-
项目类别:
-
资助金额:$16.1万
-
财政年份:2011
-
负责人:Jirair K Bedoyan
-
依托单位:
Advanced Genetic Study and Pilot Newborn Screening for Disorders of Pyruvate Metabolism
-
批准号:10700006
-
项目类别:
-
资助金额:$15.84万
-
财政年份:2011
-
负责人:Jirair K Bedoyan
-
依托单位:
Advanced Genetic Study and Pilot Newborn Screening for Disorders of Pyruvate Metabolism
-
批准号:10265498
-
项目类别:
-
资助金额:$16.1万
-
财政年份:2011
-
负责人:Jirair K Bedoyan
-
依托单位:
MOLECULAR MECHANISMS OF S POMBE MEIOTIC RECOMBINATION
-
批准号:2654914
-
项目类别:
-
资助金额:$2.62万
-
财政年份:1998
-
负责人:Jirair K Bedoyan
-
依托单位:
MOLECULAR MECHANISMS OF S POMBE MEIOTIC RECOMBINATION
-
批准号:2872617
-
项目类别:
-
资助金额:$3.25万
-
财政年份:1997
-
负责人:Jirair K Bedoyan
-
依托单位:
MOLECULAR MECHANISMS OF S POMBE MEIOTIC RECOMBINATION
-
批准号:2021345
-
项目类别:
-
资助金额:$2.43万
-
财政年份:1997
-
负责人:Jirair K Bedoyan
-
依托单位:
Advanced Genetic Study and Pilot Newborn Screening for Disorders of Pyruvate Metabolism
-
批准号:9804636
-
项目类别:
-
资助金额:$16.0万
-
财政年份:--
-
负责人:Jirair K Bedoyan
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: